[go: up one dir, main page]

CN100592373C - 液晶显示面板驱动装置及其驱动方法 - Google Patents

液晶显示面板驱动装置及其驱动方法 Download PDF

Info

Publication number
CN100592373C
CN100592373C CN200710074614A CN200710074614A CN100592373C CN 100592373 C CN100592373 C CN 100592373C CN 200710074614 A CN200710074614 A CN 200710074614A CN 200710074614 A CN200710074614 A CN 200710074614A CN 100592373 C CN100592373 C CN 100592373C
Authority
CN
China
Prior art keywords
pixel
picture
frame
gray scale
liquid crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200710074614A
Other languages
English (en)
Other versions
CN101312015A (zh
Inventor
陈景丰
陈思孝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innolux Shenzhen Co Ltd
Innolux Corp
Original Assignee
Innolux Shenzhen Co Ltd
Innolux Display Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innolux Shenzhen Co Ltd, Innolux Display Corp filed Critical Innolux Shenzhen Co Ltd
Priority to CN200710074614A priority Critical patent/CN100592373C/zh
Priority to US12/154,836 priority patent/US8054268B2/en
Publication of CN101312015A publication Critical patent/CN101312015A/zh
Application granted granted Critical
Publication of CN100592373C publication Critical patent/CN100592373C/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G3/00—Control arrangements or circuits, of interest only in connection with visual indicators other than cathode-ray tubes
    • G09G3/20—Control arrangements or circuits, of interest only in connection with visual indicators other than cathode-ray tubes for presentation of an assembly of a number of characters, e.g. a page, by composing the assembly by combination of individual elements arranged in a matrix no fixed position being assigned to or needed to be assigned to the individual characters or partial characters
    • G09G3/34—Control arrangements or circuits, of interest only in connection with visual indicators other than cathode-ray tubes for presentation of an assembly of a number of characters, e.g. a page, by composing the assembly by combination of individual elements arranged in a matrix no fixed position being assigned to or needed to be assigned to the individual characters or partial characters by control of light from an independent source
    • G09G3/36—Control arrangements or circuits, of interest only in connection with visual indicators other than cathode-ray tubes for presentation of an assembly of a number of characters, e.g. a page, by composing the assembly by combination of individual elements arranged in a matrix no fixed position being assigned to or needed to be assigned to the individual characters or partial characters by control of light from an independent source using liquid crystals
    • G09G3/3611—Control of matrices with row and column drivers
    • G09G3/3648—Control of matrices with row and column drivers using an active matrix
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G2320/00—Control of display operating conditions
    • G09G2320/02—Improving the quality of display appearance
    • G09G2320/0247—Flicker reduction other than flicker reduction circuits used for single beam cathode-ray tubes
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G2320/00—Control of display operating conditions
    • G09G2320/02—Improving the quality of display appearance
    • G09G2320/0252—Improving the response speed
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G2320/00—Control of display operating conditions
    • G09G2320/02—Improving the quality of display appearance
    • G09G2320/0261—Improving the quality of display appearance in the context of movement of objects on the screen or movement of the observer relative to the screen
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G2340/00—Aspects of display data processing
    • G09G2340/16—Determination of a pixel data signal depending on the signal applied in the previous frame
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G2360/00—Aspects of the architecture of display systems
    • G09G2360/16—Calculation or use of calculated indices related to luminance levels in display data
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G3/00—Control arrangements or circuits, of interest only in connection with visual indicators other than cathode-ray tubes
    • G09G3/20—Control arrangements or circuits, of interest only in connection with visual indicators other than cathode-ray tubes for presentation of an assembly of a number of characters, e.g. a page, by composing the assembly by combination of individual elements arranged in a matrix no fixed position being assigned to or needed to be assigned to the individual characters or partial characters
    • G09G3/2007—Display of intermediate tones
    • G09G3/2018—Display of intermediate tones by time modulation using two or more time intervals
    • G09G3/2022—Display of intermediate tones by time modulation using two or more time intervals using sub-frames
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G3/00—Control arrangements or circuits, of interest only in connection with visual indicators other than cathode-ray tubes
    • G09G3/20—Control arrangements or circuits, of interest only in connection with visual indicators other than cathode-ray tubes for presentation of an assembly of a number of characters, e.g. a page, by composing the assembly by combination of individual elements arranged in a matrix no fixed position being assigned to or needed to be assigned to the individual characters or partial characters
    • G09G3/2007—Display of intermediate tones
    • G09G3/2077—Display of intermediate tones by a combination of two or more gradation control methods
    • G09G3/2081—Display of intermediate tones by a combination of two or more gradation control methods with combination of amplitude modulation and time modulation

Landscapes

  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Computer Hardware Design (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Control Of Indicators Other Than Cathode Ray Tubes (AREA)
  • Liquid Crystal Display Device Control (AREA)

Abstract

一种液晶显示面板驱动装置，其包括一帧存储器、一比较器、一亮度检测器、一画面复杂程度计算器和一灰阶转换器。该比较器用来接收待显示的一帧画面的像素灰阶和该帧存储器输出的上一帧画面的像素灰阶，对应比较该两帧画面各像素灰阶。该亮度检测器用来检测待显示的一帧画面各个像素的亮度值。该画面复杂程度计算器用来计算待显示的一帧画面的画面复杂程度值。该灰阶转换器用来将待显示的一帧画面的像素灰阶转换成多组校正灰阶，该灰阶转换器根据比较器的比较结果、各像素的亮度值和画面复杂程度值，选择输出一组校正灰阶到液晶显示面板。

Description

液晶显示面板驱动装置及其驱动方法
技术领域
本发明是关于一种液晶显示面板驱动装置及其驱动方法。
背景技术
由于液晶显示面板具有轻、薄、耗电小等优点，被广泛应用于电视、笔记本电脑、移动电话等现代化信息设备。目前，液晶显示面板在市场上的应用越来越重要。然而，液晶的反应速度较慢的特性和液晶显示面板的稳态(Hold-Type)发光方式，导致画面存在较严重的拖影现象。
为解决上述拖影现象，业界人士最先提出一种插黑技术，即将画面显示的每一帧分为一第一子时段和一第二子时段，第一子时段显示实际画面，第二子时段显示黑画面。然，由于每两实际画面之间都会插入一黑画面，因此人眼会明显感受到画面的闪烁。其次，由于每一帧中都插入了黑画面，因此画面整体亮度会将低。
为了改善上述闪烁和亮度降低的现象，业界人士又提出一种插灰技术。请参阅图1，是一种现有技术的液晶显示面板驱动装置的示意图。该液晶显示面板驱动装置10包括一帧存储器11、一比较器12和一灰阶处理器13。该帧存储器11用来接收一待显示的第(m+1)帧画面的像素灰阶V(m+1)，并将其存储的第m帧画面的像素灰阶V(m)输出到该比较器12。其中，m＝0～59。
假设该液晶显示面板14的分辨率为I×J。该比较器12用来接收一整个第m帧画面的像素灰阶V(m)和一待显示的第(m+1)帧画面的像素灰阶V(m+1)，并对应比较第m帧画面各像素的灰阶V(m，i，j)和第(m+1)帧画面各像素的灰阶V(m+1，i，j)，输出对应的比较结果到该灰阶处理器13。其中，V(m，i，j)表示第m帧画面中第(i，j)像素的灰阶，V(m+1，i，j)表示第(m+1)帧画面中第(i，j)像素的灰阶，1≤i≤I，1≤j≤J。
该灰阶处理器13用来接收一待显示的第(m+1)帧画面的像素灰阶V(m+1)，将各个像素的像素灰阶V(m+1，i，j)转换成2组校正灰阶。每一组校正灰阶包括一校正灰阶A和一校正灰阶B。该灰阶处理器13根据该比较器12的比较结果，选择其中一组校正灰阶，并在一帧的连续两个时间段内分别输出校正灰阶A和校正灰阶B到液晶显示面板14。
请参阅图2，是两组校正灰阶对应的亮度值曲线图。其中，校正灰阶1A和校正灰阶1B分别为像素灰阶V(m+1，i，j)第一时间段内对应的灰阶和像素灰阶V(m+1，i，j)第二时间段内对应的灰阶。校正灰阶2A的亮度值大于像素灰阶V(m+1，i，j)的亮度值，校正灰阶2B的亮度值小于像素灰阶V(m+1，i，j)的亮度值，且校正灰阶2A和校正灰阶2B对应的像素的平均亮度值等于像素灰阶V(m+1，i，j)对应的亮度值。
该液晶显示面板驱动装置10的驱动方法包括如下步骤：
a.输出代表一待显示的第(m+1)帧画面的像素灰阶V(m+1)到该帧存储器11和该比较器12，同时该帧存储器11输出一整个第m帧画面的像素灰阶V(m)到该比较器12；
b.该比较器12对应比较第m帧画面各像素的灰阶V(m，i，j)和第(m+1)帧画面各像素的灰阶V(m+1，i，j)，并将各个比较结果输出到该灰阶处理器13；
c.若V(m，i，j)＝V(m+1，i，j)，即第(m+1)帧画面第(i，j)像素是静态显示；则该灰阶处理器13选择校正灰阶1，并在一帧的两个连续时间段内分别输出校正灰阶1A和校正灰阶1B到液晶显示面板14；若V(m，i，j)≠V(m+1，i，j)，即第(m+1)帧第(i，j)像素是动态显示，则该灰阶处理器13选择校正灰阶2，并在一帧中两个连续时间段内分别输出校正灰阶2A和校正灰阶2B到液晶显示面板14。
由于校正灰阶1和校正灰阶2对应的像素的平均亮度值都等于像素灰阶V(m+1，i，j)对应的亮度值，因此该液晶显示面板14的整体画面亮度不变。然而，该液晶显示面板14显示动态画面时，每一帧内都会显示一亮画面和一暗画面，因此该液晶显示面板14仍无法避免闪烁问题，影响画面显示品质。
发明内容
为了解决现有技术液晶显示面板画面显示品质较低的问题，有必要提供一种可提高液晶显示面板画面显示品质的液晶显示面板驱动装置。
为了解决现有技术液晶显示面板画面显示品质较低的问题，还有必要提供一种上述液晶显示面板驱动装置的驱动方法。
一种液晶显示面板驱动装置，其包括一帧存储器、一比较器、一亮度检测器、一画面复杂程度计算器和一灰阶转换器。该帧存储器用来接收待显示的一帧画面的像素灰阶，并输出其存储的上一帧画面的像素灰阶。该比较器用来接收待显示的一帧画面的像素灰阶和该帧存储器输出的上一帧画面的像素灰阶，对应比较该两帧画面各像素的灰阶，并输出对应的比较结果。该亮度检测器用来检测待显示的一帧画面各个像素的亮度值并输出。该画面复杂程度计算器用来计算待显示的一帧画面的画面复杂程度值并输出。该灰阶转换器用来接收待显示的一帧画面的像素灰阶，将各个像素的像素灰阶转换成多组校正灰阶，该灰阶转换器根据该比较器的比较结果、各像素的亮度值和画面复杂程度值，选择输出一组校正灰阶到一液晶显示面板。
上述液晶显示面板驱动装置的驱动方法包括如下步骤：a.代表待显示的一帧画面的像素灰阶输出到该帧存储器、该比较器、该亮度检测器和该画面复杂程度计算器，同时该帧存储器输出上一帧画面的像素灰阶到该比较器；b.该比较器对应比较该两帧画面各像素的灰阶，并将比较结果输出到该灰阶转换器；同时该亮度检测器将各像素的亮度值输出到该灰阶转换器，该画面复杂程度计算器将各阵列的画面复杂程度值输出到该灰阶转换器；c.该灰阶转换器根据该比较器输出的各像素的比较结果、各像素的亮度值和画面复杂程度值选择一组校正灰阶，输出到液晶显示面板。
相较于现有技术，该液晶显示面板驱动装置的灰阶转换器可以将每一帧画面的各像素的像素灰阶转换成多组校正灰阶，且根据各像素的亮度值和像素所在阵列的画面复杂程度值选择一组最合适的校正灰阶，既可有效克服拖影问题、又可有效克服闪烁问题。另，每一组校正灰阶对应的像素的平均显示亮度值可以控制，也可避免画面整体亮度降低的问题。因此，该液晶显示面板驱动装置和驱动方法驱动的液晶显示面板的显示品质较高。
附图说明
图1是一种现有技术的液晶显示面板驱动装置的示意图。
图2是两组校正灰阶对应的亮度值曲线图。
图3是本发明液晶显示面板驱动装置一较佳实施方式的示意图。
图4是比较结果、亮度值、画面复杂程度值与多组校正灰阶的对应关系表。
图5是多组校正灰阶对应的亮度值曲线图。
具体实施方式
请参阅图3，是本发明液晶显示面板驱动装置一较佳实施方式的示意图。该液晶显示面板驱动装置20包括一帧存储器21、一比较器22、一亮度检测器23、一画面复杂程度计算器24和一灰阶转换器25。
该帧存储器21用来接收一待显示的第(m+1)帧画面的像素灰阶V(m+1)，并将其存储的第m帧画面的像素灰阶V(m)输出到该比较器22。其中，m＝0～59。该亮度检测器23用来检测一待显示的第(m+1)帧画面各个像素的亮度值，并将亮度值输出到该灰阶转换器25。
假设该液晶显示面板驱动装置20驱动的液晶显示面板26的分辨率为1024×768。以12列16行为一个阵列，将液晶显示面板26的显示区域分为64个阵列。该画面复杂程度计算器24用来计算第(m+1)帧画面每一个阵列的画面复杂程度值，并将各画面复杂程度值输出到该灰阶转换器25。该画面复杂程度值可通过计算一阵列画面对应的灰阶数量来确定。
该比较器22用来接收一整个第m帧画面的像素灰阶V(m)和一待显示的第(m+1)帧画面的像素灰阶V(m+1)，并对应比较第m帧画面各像素的灰阶V(m，i，j)和第(m+1)帧画面各像素的灰阶V(m+1，i，j)，输出对应的比较结果到该灰阶转换器25。其中，V(m，i，j)表示第m帧画面中第(i，j)像素的灰阶，V(m+1，i，j)表示第(m+1)帧画面中第(i，j)像素的灰阶，1≤i≤I，1≤j≤J。
该灰阶转换器25用来接收一整个第(m+1)帧画面的像素灰阶V(m+1)，将各个像素的像素灰阶V(m+1，i，j)转换成多组校正灰阶。每一组校正灰阶包括一校正灰阶A和一校正灰阶B。该灰阶转换器25根据该比较器22输出的比较结果、第(m+1)帧画面该像素的亮度值和该像素所在阵列的画面复杂程度值，选择一组校正灰阶，并在一帧的连续两个时间段内分别输出校正灰阶A和校正灰阶B到液晶显示面板26。每一组校正灰阶对应的平均亮度值等于像素灰阶V(m+1，i，j)对应的亮度值。
请参阅图4，是该比较器22输出的第m帧画面第(i，j)像素的比较结果、第m帧画面第(i，j)像素的亮度值、第m帧画面第(i，j)像素所在阵列的画面复杂程度值与多组校正灰阶的对应关系表。由图4可以看出，第(i，j)像素的亮度值分为X个等级(X≥2)，第(i，j)像素所在阵列的画面复杂程度值分为Y个等级(Y≥2)，校正灰阶为(X+Y)组。其中，亮度值等级越高，则表明亮度值越大；画面复杂程度值等级越高，则表明画面复杂程度值越大。
请参阅图5，是多组校正灰阶对应的亮度值曲线图。其中，校正灰阶1A和校正灰阶1B分别为像素灰阶V(m+1，i，j)第一时间段内对应的灰阶和像素灰阶V(m+1，i，j)第二时间段内对应的灰阶。该液晶显示面板驱动装置20的驱动方法包括如下步骤：
a.输出代表一整个第(m+1)帧画面的像素灰阶V(m+1)到该帧存储器21、该比较器22、该亮度检测器23和该画面复杂程度计算器24，同时该帧存储器21输出一整个第m帧画面的像素灰阶V(m)到该比较器22；
b.该比较器22对应比较第m帧画面各像素的灰阶V(m，i，j)和第(m+1)帧画面各像素的灰阶V(m+1，i，j)，并将比较结果输出到该灰阶转换器25；同时该亮度检测器23将各像素的亮度值输出到该灰阶转换器25，该画面复杂程度计算器24将各阵列的画面复杂程度值输出到该灰阶转换器25；
c.该灰阶转换器25会根据该比较器22输出的第(i，j)像素的比较结果、该第(i，j)像素的亮度值和第(i，j)像素所在阵列的画面复杂程度值选择一组校正灰阶，并在一帧的两个连续时间段内分别输出校正灰阶A和校正灰阶B到液晶显示面板26；
该灰阶转换器25选择校正灰阶的方法如下：
若V(m，i，j)＝V(m+1，i，j)，即第(m+1)帧第(i，j)像素是静态显示；则该灰阶转换器25选择校正灰阶1，并在一帧的两个连续时间段内分别输出校正灰阶1A和校正灰阶1B到液晶显示面板26；
若V(m，i，j)≠V(m+1，i，j)，即第(m+1)帧第(i，j)像素是动态显示，则分为以下几种选择方法：
若第(i，j)像素的亮度值处于第1等级(即最暗)，且第(i，j)像素所在阵列的画面复杂程度值处于第Y等级(即最复杂)，则画面最难分辨，选择校正灰阶(X+Y-1)。如图5所示，校正灰阶(X+Y-1)的振幅最大，使画面容易分辨。
若第(i，j)像素的亮度值处于第1等级，且第(i，j)像素所在阵列的画面复杂程度值处于第(Y-1)等级，则选择校正灰阶(X+Y-2)。如图5所示，校正灰阶(X+Y-2)的振幅仅小于校正灰阶(X+Y-1)的振幅。
若第(i，j)像素的亮度值处于第1等级，且第(i，j)像素所在阵列的画面复杂程度值处于第1等级，则选择校正灰阶X。
若第(i，j)像素的亮度值处于第2等级，且第(i，j)像素所在阵列的画面复杂程度值处于第Y等级，则选择校正灰阶(X+Y-2)。
若第(i，j)像素的亮度值处于第2等级，且第(i，j)像素所在阵列的画面复杂程度值处于第(Y-1)等级，则选择校正灰阶(X+Y-3)。
若第(i，j)像素的亮度值处于第2等级，且第(i，j)像素所在阵列的画面复杂程度值处于第1等级，则选择校正灰阶(X-1)。
依次类推，若第(i，j)像素的亮度值处于第X等级(即最亮)，且第(i，j)像素所在阵列的画面复杂程度值处于第1等级(即最简单)，则选择校正灰阶2。如图5所示，校正灰阶2的振幅仅大于校正灰阶1的振幅。
相较于现有技术，该液晶显示面板驱动装置20的灰阶转换器25可以将每一帧画面的各像素的像素灰阶V(m+1，i，j)转换成多组校正灰阶，且根据各像素的亮度值和像素所在阵列的画面复杂程度值选择一组最合适的校正灰阶，既可有效克服拖影问题、又可有效克服闪烁问题。另，每一组校正灰阶对应的像素显示亮度值可以控制为等于像素灰阶V(m+1，i，j)对应的亮度值，也可避免画面整体亮度降低的问题。因此，利用该液晶显示面板驱动装置20和驱动方法驱动的液晶显示面板26的显示品质较高。
该液晶显示面板驱动装置20也可具其它多种变更设计，如：根据需要，也可以3列4行或24列32行等为一个阵列，将一帧画面分为多个阵列，以便该画面复杂程度计算器24计算每一阵列的画面复杂程度值；当液晶显示面板26较小时，也可以一整个帧画面作为一个阵列，该画面复杂程度计算器24用来计算一帧画面的画面复杂程度值。

Claims (10)

1.一种液晶显示面板驱动装置，其包括一帧存储器和一比较器，该帧存储器用来接收待显示的一帧画面的像素灰阶，并输出其存储的上一帧画面的像素灰阶，该比较器用来接收待显示的一帧画面的像素灰阶和该帧存储器输出的上一帧画面的像素灰阶，对应比较该两帧画面各像素的灰阶，并输出对应的比较结果，其特征在于：该液晶显示面板驱动装置进一步包括一亮度检测器、一画面复杂程度计算器和一灰阶转换器，该亮度检测器用来检测待显示的一帧画面各个像素的亮度值并输出，该画面复杂程度计算器，用来计算待显示的一帧画面的画面复杂程度值并输出，该灰阶转换器用来接收待显示的一帧画面的像素灰阶，将各个像素的像素灰阶转换成多组校正灰阶，该灰阶转换器根据该比较器的比较结果、各像素的亮度值和画面复杂程度值，选择输出一组校正灰阶到一液晶显示面板。
2.如权利要求1所述的液晶显示面板驱动装置，其特征在于：以一帧画面中12列16行像素为一个阵列，将一帧画面分为多个阵列，该画面复杂程度计算器用来计算待显示的每一个阵列的画面复杂程度值，并将各画面复杂程度值输出到该灰阶转换器。
3.如权利要求2所述的液晶显示面板驱动装置，其特征在于：该画面复杂程度值通过计算一阵列画面对应的灰阶数量来确定。
4.如权利要求1所述的液晶显示面板驱动装置，其特征在于：每一组校正灰阶对应的像素的平均亮度值等于像素灰阶使该像素达到的亮度值。
5.如权利要求1所述的液晶显示面板驱动装置，其特征在于：每一组校正灰阶包括一校正灰阶A和一校正灰阶B，校正灰阶A对应的像素的亮度值大于像素灰阶使该像素达到的亮度值，校正灰阶B对应的像素的亮度值小于像素灰阶使该像素达到的亮度值，该灰阶转换器在一帧的连续两个时间段内分别输出校正灰阶A和校正灰阶B到液晶显示面板。
6.如权利要求1所述的液晶显示面板驱动装置的驱动方法，其包括如下步骤：
a.代表待显示的一帧画面的像素灰阶输出到该帧存储器、该比较器、该亮度检测器和该画面复杂程度计算器，同时该帧存储器输出上一帧画面的像素灰阶到该比较器；
b.该比较器对应比较该两帧画面各像素的灰阶，并将比较结果输出到该灰阶转换器；同时该亮度检测器将各像素的亮度值输出到该灰阶转换器，该画面复杂程度计算器将各阵列的画面复杂程度值输出到该灰阶转换器；和
c.该灰阶转换器根据该比较器输出的各像素的比较结果、各像素的亮度值和画面复杂程度值选择一组校正灰阶，输出到液晶显示面板。
7.如权利要求6所述的液晶显示面板驱动装置的驱动方法，其特征在于：步骤b中，将一帧画面分为多个阵列，该画面复杂程度计算器用来计算各阵列的画面复杂程度值。
8.如权利要求7所述的液晶显示面板驱动装置的驱动方法，其特征在于：步骤c中，若该比较器输出的像素的比较结果为相等，则该灰阶转换器选择校正灰阶1，并在一帧的两个连续时间段内分别输出校正灰阶1A和校正灰阶1B到液晶显示面板，且校正灰阶1A等于校正灰阶1B也等于该像素的像素灰阶。
9.如权利要求7所述的液晶显示面板驱动装置的驱动方法，其特征在于：步骤c中，若该比较器输出的像素的比较结果为不等，则该灰阶转换器根据该像素的亮度值和该像素所在阵列的画面复杂程度值选择一组校正灰阶，并在一帧的两个连续时间段内分别输出到液晶显示面板。
10.如权利要求9所述的液晶显示面板驱动装置的驱动方法，其特征在于：步骤c中，将各像素的亮度值分为X个等级，X≥2，将各像素所在阵列的画面复杂程度值分为Y个等级，Y≥2，若该比较器输出的像素的比较结果为不等，且该像素的亮度值最小和该像素所在阵列的画面复杂程度值最大，则选择一组振幅最大的校正灰阶；若该比较器输出的比较结果为不等，且该像素的亮度值最大和该像素所在阵列的画面复杂程度值最小，则选择一组振幅最小的校正灰阶。
CN200710074614A 2007-05-25 2007-05-25 液晶显示面板驱动装置及其驱动方法 Expired - Fee Related CN100592373C (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN200710074614A CN100592373C (zh) 2007-05-25 2007-05-25 液晶显示面板驱动装置及其驱动方法
US12/154,836 US8054268B2 (en) 2007-05-25 2008-05-27 Liquid crystal display device having pairs of compensating gradations and method for driving same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN200710074614A CN100592373C (zh) 2007-05-25 2007-05-25 液晶显示面板驱动装置及其驱动方法

Publications (2)

Publication Number Publication Date
CN101312015A CN101312015A (zh) 2008-11-26
CN100592373C true CN100592373C (zh) 2010-02-24

Family

ID=40100631

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200710074614A Expired - Fee Related CN100592373C (zh) 2007-05-25 2007-05-25 液晶显示面板驱动装置及其驱动方法

Country Status (2)

Country Link
US (1) US8054268B2 (zh)
CN (1) CN100592373C (zh)

Families Citing this family (472)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2700394C (en) 2007-09-26 2017-10-24 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
MA33210B1 (fr) 2009-03-25 2012-04-02 Genentech Inc Nouveaux anticorps anti-a5b1 et leurs utilisations
CN102024403B (zh) * 2009-09-16 2013-01-16 群康科技(深圳)有限公司 改善显示器拖影现象和轨影现象的方法与相关的显示器
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
MX2012008958A (es) 2010-02-18 2012-08-23 Genentech Inc Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
BR112012022044A2 (pt) 2010-03-24 2020-08-25 Genentech Inc ''anticorpo,imunoconjugado,formulação farmacêutica,uso do anticorpo,método de tratamento,anticorpo biespecifico isolado e célula hospedeira''.
JP5940061B2 (ja) 2010-06-18 2016-06-29 ジェネンテック， インコーポレイテッド 抗ａｘｌ抗体及び使用方法
BR112013000340A2 (pt) 2010-07-09 2016-05-31 Genentech Inc anticorpo isolado que se liga a neuropilina-1 (nrp1), ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado e método de detecção da presença de nrp1 em uma amostra biológica
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
EP2600895A1 (en) 2010-08-03 2013-06-12 Hoffmann-La Roche AG Chronic lymphocytic leukemia (cll) biomarkers
CN103209709A (zh) 2010-08-05 2013-07-17 弗·哈夫曼-拉罗切有限公司 抗mhc抗体抗病毒性细胞因子融合蛋白
PE20171512A1 (es) 2010-08-13 2017-10-20 Roche Glycart Ag Anticuerpos anti-fap
TW201209063A (en) 2010-08-13 2012-03-01 Roche Glycart Ag Anti-tenascin-C A2 antibodies and methods of use
AU2011295919A1 (en) 2010-08-31 2013-03-07 Genentech, Inc. Biomarkers and methods of treatment
EP3176184B1 (en) 2010-11-10 2020-02-19 F. Hoffmann-La Roche AG Anti-bace1 antibodies for neural disease immunotherapy
WO2012083132A2 (en) 2010-12-16 2012-06-21 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
TWI589589B (zh) 2010-12-20 2017-07-01 建南德克公司 抗間皮素（ｍｅｓｏｔｈｅｌｉｎ）抗體及免疫接合物
US20120195910A1 (en) 2010-12-22 2012-08-02 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
WO2012093068A1 (en) 2011-01-03 2012-07-12 F. Hoffmann-La Roche Ag A pharmaceutical composition of a complex of an anti-dig antibody and digoxigenin that is conjugated to a peptide
PT2691417T (pt) 2011-03-29 2018-10-31 Roche Glycart Ag Variantes de fc de anticorpos
KR20140021589A (ko) 2011-04-07 2014-02-20 제넨테크, 인크. 항-fgfr4 항체 및 사용 방법
CN103608684B (zh) 2011-05-12 2016-05-04 基因泰克公司 利用框架签名肽检测动物样品中的治疗性抗体的多重反应监测lc-ms/ms方法
CN103596980B (zh) 2011-05-16 2017-08-08 霍夫曼-拉罗奇有限公司 Fgfr1激动剂及使用方法
WO2012171996A1 (en) 2011-06-15 2012-12-20 F. Hoffmann-La Roche Ag Anti-human epo receptor antibodies and methods of use
CA2835242A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
KR20140057326A (ko) 2011-08-17 2014-05-12 제넨테크, 인크. 뉴레귤린 항체 및 그의 용도
WO2013026832A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Anti-mcsp antibodies
RU2605390C2 (ru) 2011-08-23 2016-12-20 Рош Гликарт Аг Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
KR101723273B1 (ko) 2011-08-23 2017-04-04 로슈 글리카트 아게 2 개의 ｆａｂ 단편을 포함하는 fc-부재 항체 및 이용 방법
EP2756300A1 (en) 2011-09-15 2014-07-23 F.Hoffmann-La Roche Ag Methods of promoting differentiation
CA2846630A1 (en) 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
BR112014008212A2 (pt) 2011-10-05 2017-06-13 Genentech Inc método para tratar uma condição hepática, método de indução por diferenciação hepática e método de redução de proliferação anormal do ducto biliar
TW201321414A (zh) 2011-10-14 2013-06-01 Genentech Inc 抗－ＨｔｒＡ１抗體及其使用方法
WO2013056148A2 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
PH12014500925A1 (en) 2011-10-28 2014-06-09 Genentech Inc Therapeutic combinations and methods of treating melanoma
AU2012340826A1 (en) 2011-11-21 2014-05-29 Genentech, Inc. Purification of anti-c-met antibodies
US20140335084A1 (en) 2011-12-06 2014-11-13 Hoffmann-La Roche Inc. Antibody formulation
CA2854246A1 (en) 2011-12-22 2013-06-27 F. Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
PL2794651T3 (pl) 2011-12-22 2022-12-27 F.Hoffmann-La Roche Ag Kombinacje elementów wektora ekspresyjnego, nowe sposoby generowania komórek produkcyjnych i ich zastosowanie do rekombinowanej produkcji polipeptydów
SG10201805622QA (en) 2011-12-22 2018-08-30 Hoffmann La Roche Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
MX2014008157A (es) 2012-01-18 2014-10-06 Genentech Inc Anticuerpos anti-lrp5 y metodos de uso.
WO2013109856A2 (en) 2012-01-18 2013-07-25 Genentech, Inc. Methods of using fgf19 modulators
TWI464720B (zh) * 2012-02-02 2014-12-11 Novatek Microelectronics Corp 液晶顯示驅動方法及顯示裝置
US20130209473A1 (en) 2012-02-11 2013-08-15 Genentech, Inc. R-spondin translocations and methods using the same
ES2676031T3 (es) 2012-02-15 2018-07-16 F. Hoffmann-La Roche Ag Cromatografía de afinidad basada en el receptor Fc
RS58964B1 (sr) 2012-03-13 2019-08-30 Hoffmann La Roche Kombinovana terapija za lečenje karcinoma jajnika
SG11201406079TA (en) 2012-03-27 2014-10-30 Genentech Inc Diagnosis and treatments relating to her3 inhibitors
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
AR090903A1 (es) 2012-05-01 2014-12-17 Genentech Inc Anticuerpos e inmunoconjugados anti-pmel17
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
MX2014014086A (es) 2012-05-23 2015-01-26 Genentech Inc Metodo de seleccion para agentes terapeuticos.
CN104364266A (zh) 2012-06-15 2015-02-18 霍夫曼-拉罗奇有限公司 抗-pcsk9抗体,制剂,剂量给药,和使用方法
EP3138578B1 (en) 2012-07-04 2022-01-12 F. Hoffmann-La Roche AG Anti-theophylline antibodies and methods of use
MX354303B (es) 2012-07-04 2018-02-23 Hoffmann La Roche Anticuerpos de anti-biotina y metodos de uso.
JP6148729B2 (ja) 2012-07-04 2017-06-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 共有結合している抗原−抗体結合体
CN119020380A (zh) 2012-07-05 2024-11-26 弗·哈夫曼-拉罗切有限公司 表达和分泌系统
AR091703A1 (es) 2012-07-09 2015-02-25 Genentech Inc Anticuerpos e inmunoconjugados que comprenden anticuerpos anti-cd22
HK1209042A1 (zh) 2012-07-09 2016-03-24 基因泰克公司 包含抗cd79b抗體的免疫偶聯物
PE20150614A1 (es) 2012-07-09 2015-05-25 Genentech Inc Inmunoconjugados que comprenden un anticuerpo anti-cd79b ligado a un derivado de nemorrubicina
EA201590173A1 (ru) 2012-07-09 2015-09-30 Дженентек, Инк. Иммуноконъюгаты, содержащие антитела к cd22
HK1204993A1 (zh) 2012-08-07 2015-12-11 霍夫曼-拉罗奇有限公司 用於治疗成胶质细胞瘤的组合疗法
US10087250B2 (en) 2012-10-08 2018-10-02 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
WO2014072306A1 (en) 2012-11-08 2014-05-15 F. Hoffmann-La Roche Ag Her3 antigen binding proteins binding to the beta-hairpin of her3
ES2701746T3 (es) 2012-11-13 2019-02-25 Hoffmann La Roche Anticuerpos antihemaglutinina y procedimientos de uso
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
EP2945652B1 (en) 2013-01-18 2021-07-07 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
HK1211235A1 (zh) 2013-02-22 2016-05-20 霍夫曼-拉罗奇有限公司 治疗癌症和预防药物抗性的方法
HK1211301A1 (zh) 2013-02-26 2016-05-20 罗切格利卡特公司 抗mcsp抗体
WO2014138364A2 (en) 2013-03-06 2014-09-12 Genentech, Inc. Methods of treating and preventing cancer drug resistance
US10150813B2 (en) 2013-03-14 2018-12-11 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
CN105307683A (zh) 2013-03-14 2016-02-03 基因泰克公司 治疗癌症和预防癌症药物抗性的方法
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
WO2014152358A2 (en) 2013-03-14 2014-09-25 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
MX2015012326A (es) 2013-03-15 2016-03-08 Genentech Inc Anticuerpos anti-crth2 y su uso.
KR20150128707A (ko) 2013-03-15 2015-11-18 제넨테크, 인크. 간암의 진단 및 치료를 위한 조성물 및 방법
HK1214533A1 (zh) 2013-03-15 2016-07-29 基因泰克公司 治疗癌症和预防癌症耐药性的方法
NZ712314A (en) 2013-03-15 2021-07-30 Genentech Inc Biomarkers and methods of treating pd-1 and pd-l1 related conditions
CA2902910A1 (en) 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
CN105143262A (zh) 2013-04-29 2015-12-09 豪夫迈·罗氏有限公司 结合人fcrn的修饰的抗体和使用方法
CA2904805A1 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
KR20160003803A (ko) 2013-04-29 2016-01-11 에프. 호프만-라 로슈 아게 FcRn 결합이 제거된 항-IGF-1R 항체 및 혈관 눈 질환의 치료에 있어서 이의 용도
PE20151926A1 (es) 2013-05-20 2016-01-07 Genentech Inc Anticuerpos de receptores de antitransferrina y metodos de uso
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
WO2015042108A1 (en) 2013-09-17 2015-03-26 Genentech, Inc. Methods of using anti-lgr5 antibodies
WO2015044083A1 (en) 2013-09-27 2015-04-02 F. Hoffmann-La Roche Ag Thermus thermophilus slyd fkbp domain specific antibodies
KR102105102B1 (ko) * 2013-10-10 2020-04-27 삼성전자주식회사 디스플레이 장치 및 그 디스플레이 방법
CA2926084A1 (en) 2013-10-11 2015-04-16 Genentech, Inc. Nsp4 inhibitors and methods of use
TWI658052B (zh) 2013-10-18 2019-05-01 美商建南德克公司 抗－ｒｓｐｏ抗體及使用方法
CN105849280B (zh) 2013-10-23 2020-11-06 豪夫迈·罗氏有限公司 诊断和治疗嗜酸性粒细胞紊乱的方法
LT3071597T (lt) 2013-11-21 2020-10-12 F. Hoffmann-La Roche Ag Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
TW201533060A (zh) 2013-12-13 2015-09-01 Genentech Inc 抗ｃｄ３３抗體及免疫結合物
AU2014364593A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody
PE20210648A1 (es) 2013-12-17 2021-03-26 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
EP3083687A2 (en) 2013-12-17 2016-10-26 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
IL296657A (en) 2013-12-17 2022-11-01 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
CN103714751B (zh) 2013-12-30 2016-06-22 北京京东方光电科技有限公司 像素阵列及其驱动方法、显示面板和显示装置
MX373856B (es) 2014-01-03 2020-03-25 Hoffmann La Roche Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
CN111228509A (zh) 2014-01-03 2020-06-05 豪夫迈·罗氏有限公司 双特异性抗-半抗原/抗-血脑屏障受体的抗体、其复合物及其作为血脑屏障穿梭物的应用
BR112016014945A2 (pt) 2014-01-03 2018-01-23 F. Hoffmann-La Roche Ag conjugado, formulação farmacêutica e uso
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
CN111057147B (zh) 2014-01-06 2023-11-10 豪夫迈·罗氏有限公司 单价血脑屏障穿梭模块
RU2727639C2 (ru) 2014-01-15 2020-07-22 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
BR112016015693A2 (pt) 2014-01-24 2017-10-24 Genentech Inc método para tratar um câncer de próstata e anticorpo
MX388168B (es) 2014-02-08 2025-03-19 Genentech Inc Un anticuerpo anti-amiloide beta (a?) monoclonal humanizado para usarse en el tratamiento de enfermedad de alzheimer.
KR20240094017A (ko) 2014-02-08 2024-06-24 제넨테크, 인크. 알츠하이머 질환을 치료하는 방법
WO2015123325A1 (en) 2014-02-12 2015-08-20 Genentech, Inc. Anti-jagged1 antibodies and methods of use
SG11201606870XA (en) 2014-02-21 2016-09-29 Genentech Inc Anti-il-13/il-17 bispecific antibodies and uses thereof
BR112016020822A2 (pt) 2014-03-14 2017-10-03 Genentech Inc Métodos e composições para secreção de polipeptídeos heterólogos
US20170107294A1 (en) 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
LT3126394T (lt) 2014-03-31 2020-01-27 F. Hoffmann-La Roche Ag Antikūnai prieš ox40 ir jų naudojimo būdai
BR112016022345A2 (pt) 2014-03-31 2017-10-10 Genentech Inc terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
SG11201608054YA (en) 2014-04-02 2016-10-28 Hoffmann La Roche Method for detecting multispecific antibody light chain mispairing
AP2016009549A0 (en) 2014-04-18 2016-11-30 Acceleron Pharma Inc Methods for increasing red blood cell levels and treating sickle-cell disease
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
CN106414499A (zh) 2014-05-22 2017-02-15 基因泰克公司 抗gpc3抗体和免疫偶联物
WO2015179835A2 (en) 2014-05-23 2015-11-26 Genentech, Inc. Mit biomarkers and methods using the same
RU2016148616A (ru) 2014-06-11 2018-07-18 Дженентек, Инк. Анти-lgr5 антитела и их применение
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
JP2017517552A (ja) 2014-06-13 2017-06-29 ジェネンテック， インコーポレイテッド 抗癌剤耐性の治療及び防止方法
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
CA2954687A1 (en) 2014-07-10 2016-01-14 Affiris Ag Substances and methods for the use in prevention and/or treatment in huntington's disease
BR112017000130A2 (pt) 2014-07-11 2018-01-09 Genentech Inc método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
JP2017523776A (ja) 2014-07-14 2017-08-24 ジェネンテック， インコーポレイテッド 膠芽腫の診断方法及びその治療用組成物
AR101848A1 (es) 2014-09-12 2017-01-18 Genentech Inc Anticuerpos de anti-b7-h4 e inmunoconjugados
MX2017003022A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos anti-cll-1 e inmunoconjugados.
SG10201809668TA (en) 2014-09-12 2018-11-29 Genentech Inc Anti-her2 antibodies and immunoconjugates
BR112017004953A2 (pt) 2014-09-17 2017-12-05 Genentech Inc imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula
PT3262071T (pt) 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
WO2016061389A2 (en) 2014-10-16 2016-04-21 Genentech, Inc. Anti-alpha-synuclein antibodies and methods of use
US10626176B2 (en) 2014-10-31 2020-04-21 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind B7-H4
RU2017119231A (ru) 2014-11-03 2018-12-06 Дженентек, Инк. Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40
WO2016073378A1 (en) 2014-11-03 2016-05-12 Genentech, Inc. Assays for detecting t cell immune subsets and methods of use thereof
CN107075548B (zh) 2014-11-05 2021-08-10 基因泰克公司 在细菌中产生双链蛋白质的方法
US10112994B2 (en) 2014-11-05 2018-10-30 Genentech, Inc. Methods of producing two chain proteins in bacteria
MX378451B (es) 2014-11-06 2025-03-11 Hoffmann La Roche Variantes de regiòn fc con uniòn del receptor fc neonatal (fcrn) modificado y mètodos de uso.
KR20170072343A (ko) 2014-11-06 2017-06-26 제넨테크, 인크. Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
JP6576456B2 (ja) 2014-11-06 2019-09-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 修飾されたＦｃＲｎ結合特性およびプロテインＡ結合特性を有するＦｃ領域変種
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
WO2016077369A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Animal model for nephropathy and agents for treating the same
BR112017009728A2 (pt) 2014-11-10 2018-02-06 Genentech, Inc. anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
WO2016077789A1 (en) 2014-11-14 2016-05-19 The Usa, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
SG10201807625PA (en) 2014-11-17 2018-10-30 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
US11008403B2 (en) 2014-11-19 2021-05-18 Genentech, Inc. Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
CN107108745B (zh) 2014-11-19 2021-01-12 基因泰克公司 抗bace1的抗体和其用于神经疾病免疫疗法的用途
US10508151B2 (en) 2014-11-19 2019-12-17 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
FI4141032T3 (fi) 2014-11-20 2024-07-31 Hoffmann La Roche T-solua aktivoivien bispesifisten antigeeniä sitovien molekyylien ja pd-1-akselia sitovien antagonistien yhdistelmähoito
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
WO2016090210A1 (en) 2014-12-05 2016-06-09 Genentech, Inc. ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2017007491A (es) 2014-12-10 2018-05-04 Genentech Inc Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
AR103161A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
AU2015365167B2 (en) 2014-12-19 2021-07-29 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies and methods of use
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
JP2018511557A (ja) 2015-01-22 2018-04-26 中外製薬株式会社 ２種以上の抗ｃ５抗体の組み合わせおよび使用方法
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
CN107430117A (zh) 2015-03-16 2017-12-01 豪夫迈·罗氏有限公司 检测和定量IL‑13的方法和在诊断和治疗Th2相关疾病中的用途
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
US10562960B2 (en) 2015-03-20 2020-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to gp120 and their use
PH12021552158A1 (en) 2015-03-23 2022-05-02 Jounce Therapeutics Inc Antibodies to icos
CA2979732A1 (en) 2015-04-03 2016-10-06 Eureka Therapeutics, Inc. Constructs targeting afp peptide/mhc complexes and uses thereof
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
EA037293B1 (ru) 2015-04-06 2021-03-05 Акселерон Фарма Инк. Гетеромультимеры рецепторов типа i и типа ii белков суперсемейства tgf-бета
EA201792221A1 (ru) 2015-04-07 2018-08-31 ЭЛЕКТОР ЭлЭлСи Антитела против сортилина и способы их применения
CN107709364A (zh) 2015-04-07 2018-02-16 豪夫迈·罗氏有限公司 具有激动剂活性的抗原结合复合体及使用方法
EP3286315B1 (en) 2015-04-24 2021-05-26 F. Hoffmann-La Roche AG Methods of identifying bacteria comprising binding polypeptides
HK1252158A1 (zh) 2015-05-01 2019-05-17 Genentech, Inc. 掩蔽抗cd3抗體和使用方法
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
WO2016183104A1 (en) 2015-05-11 2016-11-17 Genentech, Inc. Compositions and methods of treating lupus nephritis
CA2983282A1 (en) 2015-05-12 2016-11-17 Genentech, Inc. Therapeutic and diagnostic methods for cancer
PL3303619T3 (pl) 2015-05-29 2020-10-05 F. Hoffmann-La Roche Ag Metylacja promotora PD-L1 w chorobach nowotworowych
JP7144935B2 (ja) 2015-05-29 2022-09-30 ジェネンテック， インコーポレイテッド 癌のための治療方法及び診断方法
JP2018520658A (ja) 2015-05-29 2018-08-02 ジェネンテック， インコーポレイテッド ヒト化抗エボラウイルス糖タンパク質抗体及びその使用
CN107810012A (zh) 2015-06-02 2018-03-16 豪夫迈·罗氏有限公司 使用抗il‑34抗体治疗神经疾病的组合物和方法
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
TWI790642B (zh) 2015-06-05 2023-01-21 美商建南德克公司 抗-tau抗體及使用方法
CN107810011A (zh) 2015-06-08 2018-03-16 豪夫迈·罗氏有限公司 使用抗ox40抗体治疗癌症的方法
HK1251474A1 (zh) 2015-06-08 2019-02-01 豪夫迈‧罗氏有限公司 使用抗ox40抗體和pd-1軸結合拮抗劑治療癌症的方法
AU2016276981B2 (en) 2015-06-12 2022-10-06 Alector Llc Anti-CD33 antibodies and methods of use thereof
JP7497953B2 (ja) 2015-06-12 2024-06-11 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
WO2016205176A1 (en) 2015-06-15 2016-12-22 Genentech, Inc. Antibodies and immunoconjugates
JP6996983B2 (ja) 2015-06-16 2022-02-21 ジェネンテック， インコーポレイテッド 抗ｃｌｌ－１抗体及び使用方法
EP3310811B1 (en) 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
HRP20231134T1 (hr) 2015-06-16 2024-01-05 F. Hoffmann - La Roche Ag Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu
JP2018524312A (ja) 2015-06-17 2018-08-30 ジェネンテック， インコーポレイテッド 抗ｈｅｒ２抗体及び使用方法
KR102689256B1 (ko) 2015-06-17 2024-07-30 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
WO2017004091A1 (en) 2015-06-29 2017-01-05 Genentech, Inc. Type ii anti-cd20 antibody for use in organ transplantation
CN108348578B (zh) 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2017040342A1 (en) 2015-08-28 2017-03-09 Genentech, Inc. Anti-hypusine antibodies and uses thereof
AR105634A1 (es) 2015-09-18 2017-10-25 Chugai Pharmaceutical Co Ltd Anticuerpos que se unen a il 8 y sus usos
UA125432C2 (uk) 2015-09-23 2022-03-09 Дженентек, Інк. Оптимізовані варіанти анти-vegf антитіл
KR20180083313A (ko) 2015-09-24 2018-07-20 에이비비트로, 엘엘씨 Hiv 항체 조성물 및 사용 방법
IL319106A (en) 2015-09-25 2025-04-01 Genentech Inc Anti-TIGIT antibodies and methods of use
RS62450B1 (sr) 2015-10-02 2021-11-30 Hoffmann La Roche Anti-pd1 antitela i postupci primene
KR20180053674A (ko) 2015-10-02 2018-05-23 에프. 호프만-라 로슈 아게 공자극 tnf 수용체에 특이적인 이중특이성 항체
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
JP2018534927A (ja) 2015-10-22 2018-11-29 ジョンス セラピューティクス， インコーポレイテッド Ｉｃｏｓ発現を決定する遺伝子シグネチャー
CN107614519B (zh) 2015-10-23 2022-08-05 优瑞科生物技术公司 抗体/t细胞受体嵌合构建体及其用途
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
JP6750010B2 (ja) 2015-10-30 2020-09-02 ジェネンテック， インコーポレイテッド 抗ＨｔｒＡ１抗体及びその使用方法
CN108602884B (zh) 2015-11-08 2024-06-25 豪夫迈·罗氏有限公司 筛选多特异性抗体的方法
KR20180096645A (ko) 2015-11-23 2018-08-29 악셀레론 파마 인코포레이티드 눈 질환의 치료 방법
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
PL3387015T3 (pl) 2015-12-09 2022-02-14 F. Hoffmann-La Roche Ag Przeciwciało anty-CD20 typu II do ograniczania tworzenia przeciwciał przeciwlekowych
MX2018007145A (es) 2015-12-18 2018-08-15 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones de fragmento cristalizable (fc) variantes y metodos de uso.
MY186948A (en) 2015-12-18 2021-08-26 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
HK1243439A1 (zh) 2016-01-05 2018-07-13 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
ES2837428T3 (es) 2016-01-08 2021-06-30 Hoffmann La Roche Procedimientos de tratamiento de cánceres positivos para CEA usando antagonistas de unión al eje PD-1 y anticuerpos biespecíficos anti-CEA/anti-CD3
US20190016791A1 (en) 2016-01-20 2019-01-17 Genentech, Inc. High dose treatments for alzheimer's disease
MX2018010361A (es) 2016-02-29 2019-07-08 Genentech Inc Métodos terapéuticos y de diagnóstico para el cáncer.
WO2017159699A1 (en) 2016-03-15 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
CN108700598A (zh) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
EP3865511A1 (en) 2016-04-14 2021-08-18 F. Hoffmann-La Roche AG Anti-rspo3 antibodies and methods of use
CN109154613A (zh) 2016-04-15 2019-01-04 豪夫迈·罗氏有限公司 用于监测和治疗癌症的方法
WO2017181079A2 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
SG11201809620UA (en) 2016-05-02 2018-11-29 Hoffmann La Roche The contorsbody - a single chain target binder
EP3455252B1 (en) 2016-05-11 2022-02-23 F. Hoffmann-La Roche AG Modified anti-tenascin antibodies and methods of use
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2017211731A1 (en) 2016-06-06 2017-12-14 F. Hoffmann-La Roche Ag Fusion proteins for ophthalmology with increased eye retention
KR102376582B1 (ko) 2016-06-17 2022-03-18 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체 및 사용 방법
CN116143918A (zh) 2016-06-24 2023-05-23 豪夫迈·罗氏有限公司 抗聚泛素多特异性抗体
JP6983824B2 (ja) 2016-07-04 2021-12-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規抗体フォーマット
LT3496739T (lt) 2016-07-15 2021-05-25 Acceleron Pharma Inc. Kompozicijos ir būdai, skirti plaučių hipertenzijai gydyti
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
EA201990226A1 (ru) 2016-07-27 2019-08-30 Акселерон Фарма Инк. Способы и композиции для лечения миелофиброза
MX2018015721A (es) 2016-07-29 2019-05-27 Chugai Pharmaceutical Co Ltd Anticuerpos biespecificos que exhiben actividad de funcion de cofactor fviii alternativa mejorada.
JP2019530434A (ja) 2016-08-05 2019-10-24 ジェネンテック， インコーポレイテッド アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
EP3497129A1 (en) 2016-08-08 2019-06-19 H. Hoffnabb-La Roche Ag Therapeutic and diagnostic methods for cancer
CN109689111B (zh) 2016-08-11 2024-04-05 基因泰克公司 吡咯并苯并二氮杂䓬前药及其抗体缀合物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CN116731197A (zh) 2016-09-19 2023-09-12 豪夫迈·罗氏有限公司 基于补体因子的亲和层析
SG11201900845YA (en) 2016-09-23 2019-02-27 Genentech Inc Uses of il-13 antagonists for treating atopic dermatitis
EP4026556A1 (en) 2016-10-05 2022-07-13 Acceleron Pharma Inc. Compositions and method for treating kidney disease
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
AU2017339517B2 (en) 2016-10-06 2024-03-14 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
US11555076B2 (en) 2016-10-29 2023-01-17 Genentech, Inc. Anti-MIC antibodies and methods of use
RS62589B1 (sr) 2016-11-02 2021-12-31 Jounce Therapeutics Inc Antitela na pd-1 i njihova upotreba
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
EP3551220B1 (en) 2016-12-07 2025-01-29 Genentech, Inc. Anti-tau antibodies and methods of use
CN117820467A (zh) 2016-12-07 2024-04-05 基因泰克公司 抗tau抗体和使用方法
WO2018114879A1 (en) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag Method for in vitro glycoengineering of antibodies
JP6850351B2 (ja) 2016-12-21 2021-03-31 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗体のインビトロ糖鎖工学
KR102390246B1 (ko) 2016-12-21 2022-04-22 에프. 호프만-라 로슈 아게 항체의 시험관내 글리코조작에 있어서의 효소의 재사용
WO2018132597A1 (en) 2017-01-12 2018-07-19 Eureka Therapeutics, Inc. Constructs targeting histone h3 peptide/mhc complexes and uses thereof
EP3580235B1 (en) 2017-02-10 2024-05-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
AR110873A1 (es) 2017-02-10 2019-05-08 Genentech Inc Anticuerpos contra triptasa, composiciones de estos y usos de estos
WO2018160841A1 (en) 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
KR20240150530A (ko) 2017-03-22 2024-10-15 아센디스 파마 에이에스 히드로겔 가교된 히알루론산 전구약물 조성물 및 방법
AR111249A1 (es) 2017-03-22 2019-06-19 Genentech Inc Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
CN110461360A (zh) 2017-03-27 2019-11-15 豪夫迈·罗氏有限公司 改进的抗原结合受体形式
BR112019020168A2 (pt) 2017-03-27 2020-06-02 F. Hoffmann-La Roche Ag Receptores de ligação ao antígeno, células t transduzidas, polinucleotídeo isolado, vetor, kits, métodos para tratar uma doença e para induzir a lise de uma célula alvo e uso do receptor de ligação ao antígeno
MA49131A (fr) 2017-04-21 2020-03-25 Hoffmann La Roche Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
CN110662547A (zh) 2017-04-26 2020-01-07 优瑞科生物技术公司 表达嵌合活化受体及嵌合刺激受体的细胞及其用途
WO2018200586A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
CA3059468A1 (en) 2017-04-27 2018-11-01 Tesaro, Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
CN111094335B (zh) 2017-05-15 2022-08-23 罗切斯特大学 广泛中和的抗流感单克隆抗体及其用途
KR20200014304A (ko) 2017-06-02 2020-02-10 에프. 호프만-라 로슈 아게 암의 치료를 위한 제ii형 항-cd20 항체 및 항-cd20/항-cd3 이중특이적 항체
IL271888B2 (en) 2017-07-21 2024-09-01 Genentech Inc Therapeutic and diagnostic methods for cancer
BR112019023789A2 (pt) 2017-08-03 2020-07-28 Alector Llc anticorpos anti-cd33 e métodos de uso dos mesmos
US10759870B2 (en) 2017-09-29 2020-09-01 Chugai Seiyaku Kabushiki Kaisha Multispecific antigen-binding molecules having blood coagulation factor VIII (FVIII) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ingredient
CN111295392A (zh) 2017-11-01 2020-06-16 豪夫迈·罗氏有限公司 Compbody–多价靶结合物
CA3079129C (en) 2017-11-01 2023-02-28 F. Hoffmann-La Roche Ag Trifab-contorsbody
AU2018359967A1 (en) 2017-11-06 2020-04-23 Genentech, Inc. Diagnostic and therapeutic methods for cancer
JP7394058B2 (ja) 2017-12-21 2023-12-07 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規抗原結合部分の特異性試験のためのユニバーサルレポーター細胞アッセイ
JP2021508246A (ja) 2017-12-21 2021-03-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規抗原結合部分の特異性試験のためのｃａｒ−ｔ細胞アッセイ
TWI833724B (zh) 2017-12-22 2024-03-01 美商永斯醫療股份有限公司 抗ｌｉｌｒｂ２抗體
EP3728321A1 (en) 2017-12-22 2020-10-28 F. Hoffmann-La Roche AG Use of pilra binding agents for treatment of a disease
WO2019129211A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against pd-l1
WO2019129221A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
WO2019133512A1 (en) 2017-12-29 2019-07-04 Alector Llc Anti-tmem106b antibodies and methods of use thereof
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US11713353B2 (en) 2018-01-15 2023-08-01 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against PD-1
CA3088649A1 (en) 2018-01-16 2019-07-25 Lakepharma, Inc. Bispecific antibody that binds cd3 and another target
WO2019152715A1 (en) 2018-01-31 2019-08-08 Alector Llc Anti-ms4a4a antibodies and methods of use thereof
AU2019218959A1 (en) 2018-02-08 2020-09-03 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
EP3749362A1 (en) 2018-02-09 2020-12-16 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
TWI874309B (zh) 2018-02-26 2025-03-01 美商建南德克公司 用於抗tigit拮抗劑抗體及抗pd-l1拮抗劑抗體治療之投藥
CN111742219A (zh) 2018-03-01 2020-10-02 豪夫迈·罗氏有限公司 用于新颖靶抗原结合模块的特异性测定法
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
CN116327926A (zh) 2018-03-15 2023-06-27 中外制药株式会社 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
US11958903B2 (en) 2018-03-30 2024-04-16 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
EP3778639A4 (en) 2018-04-02 2021-06-09 Mab-Venture Biopharm Co., Ltd. LYMPHOCYTE ANTIGEN-3 (LAG-3) BINDING ANTIBODY AND ITS USES
EP3775902B1 (en) 2018-04-04 2023-02-22 F. Hoffmann-La Roche AG Diagnostic assays to detect tumor antigens in cancer patients
WO2019192972A1 (en) 2018-04-04 2019-10-10 F. Hoffmann-La Roche Ag Diagnostic assays to detect tumor antigens in cancer patients
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
CA3096703A1 (en) 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
CN112218893B (zh) 2018-05-25 2025-01-14 艾利妥 抗-sirpa抗体及其使用方法
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
CN112533952B (zh) 2018-06-01 2023-03-07 大有华夏生物医药集团有限公司 治疗疾病或病况的组合物及其用途
WO2019245991A1 (en) 2018-06-18 2019-12-26 Eureka Therapeutics, Inc. Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
SG11202012446UA (en) 2018-06-23 2021-01-28 Genentech Inc Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
WO2020006374A2 (en) 2018-06-29 2020-01-02 Alector Llc Anti-sirp-beta1 antibodies and methods of use thereof
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
TWI841576B (zh) 2018-07-13 2024-05-11 大陸商南京傳奇生物科技有限公司 用於治療傳染病之共受體系統
AU2019246837B2 (en) 2018-07-13 2024-03-21 Alector Llc Anti-Sortilin antibodies and methods of use thereof
US20200171146A1 (en) 2018-07-18 2020-06-04 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
WO2020032230A1 (ja) 2018-08-10 2020-02-13 中外製薬株式会社 抗ｃｄ１３７抗原結合分子およびその使用
CN112584863A (zh) 2018-08-17 2021-03-30 Ab工作室有限公司 催化抗体和其使用方法
BR112021003016A2 (pt) 2018-08-31 2021-05-18 Alector Llc anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir um anticorpo e para prevenir, reduzir o risco ou tratar uma doença e composição farmacêutica
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CA3111458A1 (en) 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cll1 and constructs thereof
CN112955747A (zh) 2018-09-19 2021-06-11 豪夫迈·罗氏有限公司 膀胱癌的治疗和诊断方法
KR102739487B1 (ko) 2018-09-21 2024-12-10 제넨테크, 인크. 3중-음성 유방암에 대한 진단 방법
CN113196061A (zh) 2018-10-18 2021-07-30 豪夫迈·罗氏有限公司 肉瘤样肾癌的诊断和治疗方法
EP3870235A1 (en) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Conjugated chemical inducers of degradation and methods of use
JP7620546B2 (ja) 2018-11-05 2025-01-23 ジェネンテック， インコーポレイテッド 原核宿主細胞における２鎖タンパク質の産生方法
AU2019380320A1 (en) 2018-11-16 2021-06-03 Eureka Therapeutics, Inc. Antibodies to Mucin-16 and methods of use thereof
CA3119798A1 (en) 2018-12-06 2020-06-11 Genentech, Inc. Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
CN113227119A (zh) 2018-12-10 2021-08-06 基因泰克公司 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
AR117453A1 (es) 2018-12-20 2021-08-04 Genentech Inc Fc de anticuerpos modificados y métodos para utilizarlas
EP3883609A2 (en) 2018-12-20 2021-09-29 The United States of America, as represented by the Secretary, Department of Health and Human Services Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
EP3898984A1 (en) 2018-12-21 2021-10-27 Genentech, Inc. Methods of producing polypeptides using a cell line resistant to apoptosis
CN120248098A (zh) 2019-01-23 2025-07-04 豪夫迈·罗氏有限公司 在真核宿主细胞中产生多聚体蛋白质的方法
WO2020151572A1 (en) 2019-01-23 2020-07-30 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-pd-l1 diabodies and the use thereof
JPWO2020153467A1 (ja) 2019-01-24 2021-12-02 中外製薬株式会社 新規がん抗原及びそれらの抗原に対する抗体
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
CN114026122B (zh) 2019-02-21 2024-12-31 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
JP2022521773A (ja) 2019-02-27 2022-04-12 ジェネンテック， インコーポレイテッド 抗ｔｉｇｉｔ抗体と抗ｃｄ２０抗体又は抗ｃｄ３８抗体とによる処置のための投薬
EP3935385A1 (en) 2019-03-08 2022-01-12 F. Hoffmann-La Roche AG Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles
CA3130862A1 (en) 2019-03-29 2020-10-08 Genentech, Inc. Modulators of cell surface protein interactions and methods and compositions related to same
CA3134522A1 (en) 2019-04-19 2020-10-22 Genentech, Inc. Anti-mertk antibodies and their methods of use
WO2020227228A2 (en) 2019-05-03 2020-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
WO2020232169A1 (en) 2019-05-14 2020-11-19 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma
US20230085439A1 (en) 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
BR112021025077A2 (pt) 2019-06-11 2022-05-03 Alector Llc Anticorpos anti-sortilina para uso em terapia
CN119954954A (zh) 2019-07-31 2025-05-09 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法
TWI780464B (zh) 2019-08-06 2022-10-11 香港商新旭生技股份有限公司 結合至病理性ｔａｕ種類之抗體及其用途
US12098212B2 (en) 2019-08-12 2024-09-24 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
WO2021050645A1 (en) 2019-09-12 2021-03-18 Genentech, Inc. Compositions and methods of treating lupus nephritis
EP4031580A1 (en) 2019-09-20 2022-07-27 F. Hoffmann-La Roche AG Dosing for anti-tryptase antibodies
PE20221110A1 (es) 2019-09-27 2022-07-11 Genentech Inc Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
EP4036116A4 (en) 2019-09-27 2024-01-24 Nanjing GenScript Biotech Co., Ltd. ANTI-VHH DOMAIN ANTIBODIES AND USE THEREOF
WO2021059075A1 (en) 2019-09-27 2021-04-01 Janssen Biotech, Inc. Anti-ceacam antibodies and uses thereof
KR20220086618A (ko) 2019-10-18 2022-06-23 제넨테크, 인크. 미만성 거대 B-세포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
CN115066613A (zh) 2019-11-06 2022-09-16 基因泰克公司 用于治疗血液癌症的诊断和治疗方法
KR20220113790A (ko) 2019-12-13 2022-08-16 제넨테크, 인크. 항-ly6g6d 항체 및 사용 방법
JP2023506465A (ja) 2019-12-13 2023-02-16 アレクトル エルエルシー 抗ＭｅｒＴＫ抗体及びその使用方法
AU2019479791B2 (en) 2019-12-27 2024-05-02 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
US20230096452A1 (en) 2020-02-10 2023-03-30 Shanghai Escugen Biotechnology Co., Ltd. Claudin 18.2 antibody and use thereof
AU2021220887B2 (en) 2020-02-10 2024-11-21 Shanghai Escugen Biotechnology Co., Ltd. CLDN18.2 antibody and use thereof
TW202144395A (zh) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
CN115087488A (zh) 2020-02-14 2022-09-20 震动疗法股份有限公司 与ccr8结合的抗体和融合蛋白及其用途
BR112022016491A2 (pt) 2020-02-28 2022-10-11 Shanghai Henlius Biotech Inc Construto anti-cd137 e usos do mesmo
KR20220145859A (ko) 2020-02-28 2022-10-31 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물, 다중 특이적 항체 및 그 용도
CA3174680A1 (en) 2020-03-13 2021-09-16 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
KR102811560B1 (ko) 2020-03-19 2025-05-22 제넨테크, 인크. 동종형 선택적 항-tgf-베타 항체 및 이용 방법
MX2022011752A (es) 2020-03-24 2022-10-18 Genentech Inc Agentes de fijacion a tie2 y metodos de uso.
EP4126937A1 (en) 2020-03-31 2023-02-08 Alector LLC Anti-mertk antibodies and methods of use thereof
JP2023519930A (ja) 2020-04-01 2023-05-15 ユニバーシティ オブ ロチェスター インフルエンザｈ３ｎ２ウイルスのヘマグルチニン（ｈａ）およびノイラミニダーゼ（ｎａ）に対するモノクローナル抗体
WO2021202959A1 (en) 2020-04-03 2021-10-07 Genentech, Inc. Therapeutic and diagnostic methods for cancer
TW202206111A (zh) 2020-04-24 2022-02-16 美商建南德克公司 使用抗ｃｄ７９ｂ免疫結合物之方法
JP2023523450A (ja) 2020-04-28 2023-06-05 ジェネンテック， インコーポレイテッド 非小細胞肺がん免疫療法のための方法及び組成物
WO2021222935A2 (en) 2020-04-28 2021-11-04 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
WO2021225892A1 (en) 2020-05-03 2021-11-11 Levena (Suzhou) Biopharma Co., Ltd. Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same
EP4157881A4 (en) 2020-05-27 2024-10-09 Staidson (Beijing) Biopharmaceuticals Co., Ltd. ANTIBODIES THAT SPECIFICALLY RECOGNIZE NERVE GROWTH FACTOR AND THEIR USES
IL298735A (en) 2020-06-02 2023-02-01 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
JP2023529206A (ja) 2020-06-12 2023-07-07 ジェネンテック， インコーポレイテッド がん免疫療法のための方法及び組成物
KR20230025691A (ko) 2020-06-16 2023-02-22 제넨테크, 인크. 삼중 음성 유방암을 치료하기 위한 방법과 조성물
BR112022025801A2 (pt) 2020-06-18 2023-10-03 Hoffmann La Roche Métodos para tratar um paciente e para tratar um paciente com escc avançado, kit, anticorpo, uso de um anticorpo e uso de um antagonista de ligação
CR20230017A (es) 2020-07-21 2023-02-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpo de brm y métodos de estos
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
JP2023536461A (ja) 2020-07-29 2023-08-25 ダイナミキュア バイオテクノロジー エルエルシー 抗ｃｄ９３構築物およびその使用
CN114360436B (zh) 2020-09-28 2023-03-10 京东方科技集团股份有限公司 补偿显示画面的方法、装置、设备及显示屏驱动板
CN116685325A (zh) 2020-10-20 2023-09-01 豪夫迈·罗氏有限公司 Pd-1轴结合拮抗剂和lrrk2抑制剂的组合疗法
WO2022090181A1 (en) 2020-10-28 2022-05-05 F. Hoffmann-La Roche Ag Improved antigen binding receptors
TWI838660B (zh) 2020-11-04 2024-04-11 美商建南德克公司 以抗cd20/抗cd3雙特異性抗體和抗cd79b抗體藥物結合物治療的給藥方法
WO2022098628A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
US11919945B2 (en) 2020-11-04 2024-03-05 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies
AU2021374592A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
KR20230117169A (ko) 2020-12-02 2023-08-07 알렉터 엘엘씨 항-소르틸린 항체의 사용 방법
MX2023006649A (es) 2020-12-07 2023-06-21 UCB Biopharma SRL Anticuerpos contra interleucina-22.
IL303295A (en) 2020-12-07 2023-07-01 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
CA3204702A1 (en) 2020-12-17 2022-06-23 F. Hoffmann-La Roche Ag Anti-hla-g antibodies and use thereof
WO2022132904A1 (en) 2020-12-17 2022-06-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies targeting sars-cov-2
WO2023250402A2 (en) 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
EP4277926A1 (en) 2021-01-15 2023-11-22 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
US20240117011A1 (en) 2021-02-09 2024-04-11 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Antibodies targeting the spike protein of coronaviruses
WO2022173689A1 (en) 2021-02-09 2022-08-18 University Of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens
CA3210069A1 (en) 2021-03-03 2022-09-09 Tong Zhu Antibody-drug conjugates comprising an anti-bcma antibody
TW202302646A (zh) 2021-03-05 2023-01-16 美商當康生物科技有限公司 抗vista構築體及其用途
KR20230156373A (ko) 2021-03-15 2023-11-14 제넨테크, 인크. 루푸스 신염의 치료 조성물 및 치료 방법
WO2022197947A1 (en) 2021-03-18 2022-09-22 Alector Llc Anti-tmem106b antibodies and methods of use thereof
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
US20240166738A1 (en) 2021-03-23 2024-05-23 Alector Llc Anti-tmem106b antibodies for treating and preventing coronavirus infections
US20240150466A1 (en) 2021-03-25 2024-05-09 Dynamicure Biotechnology Llc Anti-igfbp7 constructs and uses thereof
AR125344A1 (es) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd Anticuerpo anti-c1s
EP4329800A1 (en) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
EP4330282A1 (en) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
KR20240004694A (ko) 2021-05-03 2024-01-11 유씨비 바이오파마 에스알엘 항체
US20240218057A1 (en) 2021-05-06 2024-07-04 The Rockefeller University Neutralizing anti- sars-cov-2 antibodies and methods of use thereof
AU2022273063A1 (en) 2021-05-12 2023-11-23 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
CN113278071B (zh) 2021-05-27 2021-12-21 江苏荃信生物医药股份有限公司 抗人干扰素α受体1单克隆抗体及其应用
WO2022255440A1 (en) 2021-06-04 2022-12-08 Chugai Seiyaku Kabushiki Kaisha Anti-ddr2 antibodies and uses thereof
AU2022289684A1 (en) 2021-06-09 2023-10-05 F. Hoffmann-La Roche Ag Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
JP2024527262A (ja) 2021-06-16 2024-07-24 アレクトル エルエルシー 二重特異性抗ＭｅｒＴＫ及び抗ＰＤＬ１抗体ならびにその使用方法
WO2022266221A1 (en) 2021-06-16 2022-12-22 Alector Llc Monovalent anti-mertk antibodies and methods of use thereof
WO2022266660A1 (en) 2021-06-17 2022-12-22 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
AU2022299846B2 (en) 2021-06-25 2024-08-15 Chugai Seiyaku Kabushiki Kaisha Anti–ctla-4 antibody
JP7477127B2 (ja) 2021-06-25 2024-05-01 中外製薬株式会社 抗ｃｔｌａ－４抗体の使用
US20250011448A1 (en) 2021-07-08 2025-01-09 Staidson Biopharma Inc. Antibodies specifically recognizing tnfr2 and uses thereof
KR20240058075A (ko) 2021-07-14 2024-05-03 스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드 Cd40을 특이적으로 식별하는 항체 및 이의 응용
WO2023004386A1 (en) 2021-07-22 2023-01-26 Genentech, Inc. Brain targeting compositions and methods of use thereof
EP4384553A1 (en) 2021-08-13 2024-06-19 Genentech, Inc. Dosing for anti-tryptase antibodies
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
WO2023034750A1 (en) 2021-08-30 2023-03-09 Genentech, Inc. Anti-polyubiquitin multispecific antibodies
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
CN113603775B (zh) 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
AR127269A1 (es) 2021-10-08 2024-01-03 Chugai Pharmaceutical Co Ltd Formulación de anticuerpo anti-hla-dq2.5
EP4419558A1 (en) 2021-10-19 2024-08-28 Alector LLC Anti-cd300lb antibodies and methods of use thereof
JP2024544885A (ja) 2021-11-10 2024-12-05 ジェネンテック， インコーポレイテッド 抗インターロイキン－３３抗体及びその使用
TW202337494A (zh) 2021-11-16 2023-10-01 美商建南德克公司 用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物
TW202333787A (zh) 2021-12-01 2023-09-01 日商中外製藥股份有限公司 含抗體製劑的調製方法
CN116829179A (zh) 2021-12-06 2023-09-29 北京三诺佳邑生物技术有限责任公司 特异性结合肺炎克雷伯菌o2抗原和o1抗原的双特异性抗体以及组合物
JP2025501522A (ja) 2021-12-17 2025-01-22 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ｏｘ４０抗体及び使用方法
CN118488965A (zh) 2021-12-17 2024-08-13 上海复宏汉霖生物技术股份有限公司 抗ox40抗体、多特异性抗体及其使用方法
EP4469159A1 (en) 2022-01-27 2024-12-04 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
CN118984836A (zh) 2022-02-10 2024-11-19 美国政府(由卫生和人类服务部的部长所代表) 广泛靶向冠状病毒的人单克隆抗体
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
JP2025512785A (ja) 2022-03-23 2025-04-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体及び化学療法の併用処置
EP4499230A1 (en) 2022-03-25 2025-02-05 F. Hoffmann-La Roche AG Improved chimeric receptors
CN118974096A (zh) 2022-03-25 2024-11-15 上海复宏汉霖生物技术股份有限公司 抗msln抗体及使用方法
AU2023251832A1 (en) 2022-04-13 2024-10-17 F. Hoffmann-La Roche Ag Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
TW202400262A (zh) 2022-04-26 2024-01-01 日商中外製藥股份有限公司 含有醫藥製劑的內含過濾器之注射器
JP2025515486A (ja) 2022-04-29 2025-05-15 ピュリノミア バイオテック， インコーポレイテッド 好酸球駆動性疾患及び障害を治療するための方法及び組成物
IL316223A (en) 2022-05-03 2024-12-01 Genentech Inc Anti-LY6E antibodies, immunoconjugates and their uses
WO2023217068A1 (zh) 2022-05-09 2023-11-16 舒泰神（北京）生物制药股份有限公司 特异性识别gdf15的抗体及其应用
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
EP4537107A2 (en) 2022-06-07 2025-04-16 Genentech, Inc. Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody
EP4558226A1 (en) 2022-07-19 2025-05-28 Staidson Biopharma Inc. Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
MA71628A (fr) 2022-07-29 2025-05-30 Alector Llc Anticorps anti-gpnmb et leurs méthodes d'utilisation
CN115188313B (zh) * 2022-07-29 2024-11-29 武汉天马微电子有限公司 一种显示面板的控制方法及装置、显示设备和存储介质
CN119584983A (zh) 2022-07-29 2025-03-07 艾莱克特有限责任公司 Cd98hc抗原结合结构域及其用途
WO2024030829A1 (en) 2022-08-01 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024049949A1 (en) 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
WO2024054822A1 (en) 2022-09-07 2024-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered sars-cov-2 antibodies with increased neutralization breadth
CN120077071A (zh) 2022-09-07 2025-05-30 当康生物技术有限责任公司 抗vista构建体及其用途
WO2024067344A1 (zh) 2022-09-27 2024-04-04 舒泰神（北京）生物制药股份有限公司 特异性识别light的抗体及其应用
WO2024083021A1 (zh) 2022-10-20 2024-04-25 北京三诺佳邑生物技术有限责任公司 特异性结合TRAIL或FasL的抗体组合以及双特异性抗体
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
CN115724975A (zh) 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用
WO2024097741A1 (en) 2022-11-04 2024-05-10 Gilead Sciences, Inc. Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
CN120152990A (zh) 2022-11-08 2025-06-13 基因泰克公司 治疗儿童期发作的特发性肾病综合征的组合物和方法
WO2024137381A1 (en) 2022-12-19 2024-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies for treating sars-cov-2 infection
WO2024138151A1 (en) 2022-12-22 2024-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees
WO2024148232A2 (en) 2023-01-06 2024-07-11 Alector Llc Anti-il18 binding protein antibodies and methods of use thereof
WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
WO2024233646A1 (en) 2023-05-10 2024-11-14 Genentech, Inc. Methods and compositions for treating cancer
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof
WO2025117384A1 (en) 2023-12-01 2025-06-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing influenza hemagglutinin stem-directed antibodies
WO2025129010A1 (en) 2023-12-14 2025-06-19 Genentech, Inc. Methods of structure determination using antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10333631A (ja) * 1997-06-02 1998-12-18 Daichiyuu Denshi:Kk 拡張型表示装置および拡張型表示装置を用いた表示システム
US6278434B1 (en) * 1998-10-07 2001-08-21 Microsoft Corporation Non-square scaling of image data to be mapped to pixel sub-components
GB0006811D0 (en) 2000-03-22 2000-05-10 Koninkl Philips Electronics Nv Controller ICs for liquid crystal matrix display devices
TW518882B (en) * 2000-03-27 2003-01-21 Hitachi Ltd Liquid crystal display device for displaying video data
JP2002323876A (ja) * 2001-04-24 2002-11-08 Nec Corp 液晶表示装置における画像表示方法及び液晶表示装置
US7587671B2 (en) * 2005-05-17 2009-09-08 Palm, Inc. Image repositioning, storage and retrieval
CN100380189C (zh) 2006-03-10 2008-04-09 友达光电股份有限公司 液晶显示面板动态影像的显示方法

Also Published As

Publication number Publication date
US20090002360A1 (en) 2009-01-01
US8054268B2 (en) 2011-11-08
CN101312015A (zh) 2008-11-26

Similar Documents

Publication Publication Date Title
CN100592373C (zh) 液晶显示面板驱动装置及其驱动方法
US9530380B2 (en) Display device and driving method thereof
US8416269B2 (en) Liquid crystal display device and driving method thereof
CN107845370B (zh) 一种显示面板的显示方法、显示面板及显示装置
CN101051449B (zh) 数据转换装置和方法及图像显示装置的驱动装置和方法
KR101337042B1 (ko) 터치패널 표시장치 및 그의 구동방법
KR20160109905A (ko) 게이트 드라이버, 디스플레이 구동 회로 및 디스플레이 장치
CN111312143B (zh) 显示装置及其驱动方法和驱动装置、计算机可读存储介质
US20120162178A1 (en) Liquid crystal display device and method for driving the same
CN101739983B (zh) 包括图像信号处理器和图像插值芯片的显示装置
JP2005148710A (ja) 液晶表示装置の駆動方法及び駆動装置
CN102214450B (zh) 液晶显示器及其驱动方法
CN114495791A (zh) 显示面板的显示控制方法、装置及显示装置
US20100026617A1 (en) Method and device for activating scan lines of a passive matrix liquid crystal display (lcd) panel
CN101320544B (zh) 数据处理电路、液晶显示装置及其驱动方法
CN114846536B (zh) 数据处理方法及装置、显示装置
KR20150086826A (ko) 표시 장치 및 그 구동 방법
US20080297458A1 (en) Liquid crystal display using combination dot inversion driving method and driving method thereof
CN113870808B (zh) 一种时序控制方法、时序控制器、存储介质和计算机设备
CN102568399B (zh) 过驱动值产生方法
CN104332145B (zh) 液晶面板及其驱动方法、液晶显示器
US11335276B2 (en) Display driving device and driving method of adjusting brightness of image based on ambient illumination
CN101593494A (zh) 液晶显示器及其驱动方法
KR101409540B1 (ko) 액정표시장치 및 그의 구동방법
KR101351888B1 (ko) 액정표시장치와 그 구동방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100224

Termination date: 20200525

CF01 Termination of patent right due to non-payment of annual fee